Apnimed

Based in Cambridge, Massachusetts, Apnimed is a clinical-stage pharmaceutical company developing oral medications to treat obstructive sleep apnea and related sleep disorders. The biotechnology firm focuses on creating a once-daily pharmacological alternative to traditional continuous positive airway pressure machines and surgical treatments. Originating from initial research conducted at Brigham and Women’s Hospital, the enterprise operates with an estimated 50 to 100 employees. The privately held company has raised over $150 million in total funding to date, including a $79.75 million Series C financing round secured to advance Phase 3 clinical trials for its lead drug candidate, AD109. This ongoing clinical development is supported by venture capital investments from prominent institutional backers such as Alpha Wave Ventures, Sectoral Asset Management, and Morningside Ventures. Apnimed was founded in 2017 by Larry Miller, Andrew Wellman, and David White.